Drug discovery is a process where a new drug or medications are discovered and aims to identify a compound therapeutically useful in curing and treating disease. It includes a wide range of scientific divisions, including biology, chemistry, and pharmacology.
This process associates with the identification of candidates, synthesis, characterization, validation, optimization, screening, and assays for therapeutic efficacy.
The three major phases are:
Drug Development Phases includes:
Drug screening is a process where potential drugs are identified and optimized before the selection of a candidate drug to progress to clinical trials. It can involve screening large volumes of chemicals for a particular biological activity in high-throughput screening assays.
Drug screening mainly includes In-vivo and In-vivo models for drug screening
Title : New approach to hyponatremia yields high prevalence and identification of natriuretic protein that causes renal salt wasting (RSW) and new syndrome of RSW in alzheimer’s disease
John K Maesaka, NYU Long Island School of Medicine, United States
Title : Synergism in the permeability of the blood Brain barrier between heavy metals and electromagnetic fields
Bartolome Ribas Ozonas, Royal National Academy of Pharmacy, Spain
Title : Chameleon nanocarriers for dynamic delivery of RNA Medicines
Ernst Wagner, Ludwig-Maximilians-Universitat Munich, Germany
Title : Mucoadhesive electrospun fibers in oral drug delivery
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Human nanomedicine: Emphasizing results of nanomaterials in humans
Thomas J. Webster, Hebei University of Technology, China
Title : Qualitative and quantitative measures of drugs’ placenta permeability - A chromatographic and computational approach
Anna Weronika Sobanska, Medical University of Lodz, Poland
Title : Manufacturing outlook on cell and Gene and aseptic processing according the EU GMP Annex 1
Richard Denk, SKAN AG, Switzerland
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : New approaches to inhibit miRNAs in an atherosclerosis pre-clinical model
Noemi Rotllan Vila, IIB SANT PAU and CIBERDEM, Spain
Title : The role of non-antibiotic drugs on the development of antibiotic resistance
Mujde Eryilmaz, Ankara University, Turkey